Diabetes, not CEO, dominates Sanofi earnings

American depository shares of Sanofi (Euronext:SAN; NYSE:SNY) fell $4.75 to $48.07 in New York on Tuesday as the company revealed that sales in its diabetes franchise would be flat in 2015 primarily because of competitive pricing in the U.S.

Diabetes product sales grew 8.1% overall to EUR 1.8 billion ($2.3 billion) at constant exchange rates, but U.S. growth of Lantus insulin glargine was limited to 5.8%. Overall, the company said group sales were up 5.1% to EUR 8.8 billion in the quarter and reiterated that it expected core business EPS to be 6-8% over 2013 at constant exchange rates. ...